Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 31 May 1991:
Vol. 252. no. 5010, pp. 1310 - 1313
DOI: 10.1126/science.1925544
Prev | Table of Contents | Next

Articles

Science, Vol 252, Issue 5010, 1310-1313
Copyright © 1991 by American Association for the Advancement of Science

articles

Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus

DC Kaslow, SN Isaacs, IA Quakyi, RW Gwadz, B Moss, and DB Keister

Malaria Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.

Many candidate antigens of malaria vaccines have limited immunological recognition. One exception is Pfs25, a cysteine-rich, 25-kilodalton sexual stage surface protein of Plasmodium falciparum. Pfs25 is a target of monoclonal antibodies that block transmission of malaria from vertebrate host to mosquito vector. The surface of mammalian cells infected with a recombinant vaccinia virus that expressed Pfs25 specifically bound transmission-blocking monoclonal antibodies. Furthermore, major histocompatibility complex-disparate congenic mouse strains immunized with recombinant Pfs25 elicited transmission-blocking antibodies, demonstrating that the capacity to develop transmission-blocking antibodies is not genetically restricted in mice. Live recombinant viruses may provide an inexpensive, easily administered alternative to subunit vaccines prepared from purified recombinant proteins to block transmission of malaria in developing countries.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Induction of Plasmodium falciparum Transmission-Blocking Antibodies in Nonhuman Primates by a Combination of DNA and Protein Immunizations.
C. Coban, M. T. Philipp, J. E. Purcell, D. B. Keister, M. Okulate, D. S. Martin, and N. Kumar (2004)
Infect. Immun. 72, 253-259
   Abstract »    Full Text »    PDF »
Effect of CpG Oligodeoxynucleotides on the Immunogenicity of Pfs25, a Plasmodium falciparum Transmission-Blocking Vaccine Antigen.
C. Coban, K. J. Ishii, A. W. Stowers, D. B. Keister, D. M. Klinman, and N. Kumar (2004)
Infect. Immun. 72, 584-588
   Abstract »    Full Text »    PDF »
A Region of Plasmodium falciparum Antigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking Antibodies.
A. W. Stowers, D. B. Keister, O. Muratova, and D. C. Kaslow (2000)
Infect. Immun. 68, 5530-5538
   Abstract »    Full Text »    PDF »
Identification of the Plasmodium chabaudi Homologue of Merozoite Surface Proteins 4 and 5 of Plasmodium falciparum.
C. G. Black, L. Wang, A. R. Hibbs, E. Werner, and R. L. Coppel (1999)
Infect. Immun. 67, 2075-2081
   Abstract »    Full Text »    PDF »
Immunization of Mice with DNA-Based Pfs25 Elicits Potent Malaria Transmission-Blocking Antibodies.
C. A. Lobo, R. Dhar, and N. Kumar (1999)
Infect. Immun. 67, 1688-1693
   Abstract »    Full Text »    PDF »
Isolation and Functional Characterization of Two Distinct Sexual-Stage-Specific Promoters of the Human Malaria Parasite Plasmodium falciparum.
K. J. Dechering, A. M. Kaan, W. Mbacham, D. F. Wirth, W. Eling, R. N. H. Konings, and H. G. Stunnenberg (1999)
Mol. Cell. Biol. 19, 967-978
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)